Disciplined Growth Investors Inc. MN Purchases 440,107 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Disciplined Growth Investors Inc. MN grew its position in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 21.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 2,527,435 shares of the company's stock after acquiring an additional 440,107 shares during the period. Myriad Genetics accounts for approximately 1.3% of Disciplined Growth Investors Inc. MN's investment portfolio, making the stock its 26th biggest position. Disciplined Growth Investors Inc. MN owned 2.78% of Myriad Genetics worth $69,226,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Assenagon Asset Management S.A. boosted its holdings in Myriad Genetics by 26.7% in the second quarter. Assenagon Asset Management S.A. now owns 250,524 shares of the company's stock valued at $6,128,000 after acquiring an additional 52,813 shares during the last quarter. Blue Trust Inc. lifted its stake in Myriad Genetics by 26.6% during the 2nd quarter. Blue Trust Inc. now owns 11,259 shares of the company's stock valued at $275,000 after acquiring an additional 2,365 shares in the last quarter. Neo Ivy Capital Management bought a new position in shares of Myriad Genetics during the second quarter valued at about $85,000. Fifth Third Bancorp boosted its stake in shares of Myriad Genetics by 1.4% in the 2nd quarter. Fifth Third Bancorp now owns 81,754 shares of the company's stock worth $2,000,000 after buying an additional 1,139 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its position in Myriad Genetics by 3.9% in the second quarter. Louisiana State Employees Retirement System now owns 45,500 shares of the company's stock worth $1,113,000 after purchasing an additional 1,700 shares during the last quarter. Institutional investors and hedge funds own 99.02% of the company's stock.

Myriad Genetics Stock Up 2.9 %

Shares of MYGN traded up $0.43 during trading hours on Tuesday, hitting $15.31. The company had a trading volume of 372,765 shares, compared to its average volume of 745,310. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -11.45 and a beta of 1.88. The firm has a fifty day moving average price of $19.78 and a 200-day moving average price of $23.81. Myriad Genetics, Inc. has a 52-week low of $14.34 and a 52-week high of $29.30. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on MYGN. Leerink Partnrs downgraded shares of Myriad Genetics from a "strong-buy" rating to a "hold" rating in a research report on Monday. Morgan Stanley lowered their target price on shares of Myriad Genetics from $32.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Monday, November 18th. Piper Sandler dropped their price objective on shares of Myriad Genetics from $30.00 to $24.00 and set a "neutral" rating for the company in a report on Monday, November 11th. Leerink Partners lowered shares of Myriad Genetics from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $30.00 to $21.00 in a report on Monday. Finally, UBS Group began coverage on shares of Myriad Genetics in a report on Tuesday. They issued a "neutral" rating and a $18.00 target price on the stock. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $25.42.

Insiders Place Their Bets

In other news, CEO Paul J. Diaz sold 15,000 shares of the business's stock in a transaction on Friday, October 11th. The stock was sold at an average price of $22.93, for a total value of $343,950.00. Following the completion of the transaction, the chief executive officer now owns 962,378 shares in the company, valued at $22,067,327.54. The trade was a 1.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.10% of the company's stock.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.